MedTrace Logo

Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D Vaccination

NCT04083430 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-03-27

No results posted yet for this study

Summary

Investigating cytotoxicity of yellow fever specific CD8 T cells following YF-17D vaccination and the following licensing of these epitope-specific CD8 T cells

Conditions

  • Healthy
  • Cytotoxicity
  • Yellow Fever Vaccination Reaction

Interventions

DRUG

Yellow Fever Vaccine

STAMARIL, powder and solvent for suspension for injection in pre-filled syringe. After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU. Powder and solvent for suspension for injection. Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution.

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jesper D Gunst, MD · Aarhus University Hospital

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-08
Primary Completion
2025-02-15
Completion
2025-12-15

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04083430 on ClinicalTrials.gov